NeonMind Biosciences Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NMDBF research report →
Price Chart
About the company
NeonMind Biosciences Inc. specializes in the research, formulation, and commercialization of medicinal and psychedelic fungi aimed at treating mental health conditions. The company is actively developing a line of psilocybin-derived products, featuring various mushroom-infused preparations, specifically tailored for weight loss and management.
- CEO
- Penny Olga White BA, LLB
- IPO
- 2021
- HQ
- Oakville, ON, CA
Get TickerSpark's AI analysis on NMDBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.54K
- P/E
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.00
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 366.65%
- ROIC
- 315.46%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-1,751,000
- Net Income
- $-2,034,000+71.8%
- EPS
- $-53.93-635.7%
- OCF Growth
- +81.4%
- FCF Growth
- +81.4%
- 52W High
- $0.23
- 52W Low
- $0.00
- 50D MA
- $0.23
- 200D MA
- $0.10
- Beta
- -0.88
- RSI (14)
- 44
- Avg Volume
- 0
No earnings-call transcripts are available for NMDBF yet.
- Free Float
- 0.0%
- Shares Outstanding
- 1.12M
- Float Shares
- 0
Our NMDBF coverage
Recent articles, reports, and earnings notes.
No research on NMDBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NMDBF report →NeonMind to Present at H.C. Wainwright Bioconnect Conference
accesswire.com · Jan 6
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
accesswire.com · Dec 2
NeonMind to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
prnewswire.com · Oct 7
NeonMind Advances Strategy for Specialty Clinic Launch
accesswire.com · Sep 28
NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD.
accesswire.com · Sep 22
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
accesswire.com · Sep 16
NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets
accesswire.com · Sep 13
NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
accesswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.